10975 North Torrey Pines Road
About Ambrx, Inc.
Ambrx®, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties. We call this process Protein Medicinal Chemistry™.
Protein Medicinal Chemistry™ can optimize any protein or antibody to create potentially best-in-class therapeutics such as long-acting proteins, bi-specifics and antibody drug conjugates. The Ambrx advantage allows us to safely and effectively target cytotoxic agents or recruit effector function to tumor cells (oncology) or modulate biological pathways implicated in disease areas such as autoimmune, metabolic and cardiovascular.
At Ambrx, we are dedicated to assembling and developing an exceptional team and a novel technology to create the next generation of protein-based medicines.
89 articles about Ambrx, Inc.
Mergers and acquisitions are trending upward as Novo Nordisk, Gilead, and Johnson & Johnson kick off the year with big deals. AI and other scientific advances will likely be the focus of M&As yet to come.
Ambrx Biopharma, Inc., or Ambrx, announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx’s closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion.
Ambrx Biopharma, Inc., or Ambrx, announced that the Company will be added to the NASDAQ Biotechnology Index, effective prior to the market open on Monday, December 18, 2023.
Ambrx Biopharma Inc., Ambrx, announced that it will host an in-person key opinion leader event during the European Society for Medical Oncology Congress 2023.
Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced the closing of its previously announced market-priced registered direct offering of approximately $75 million (the “Offering”) of its American Depositary Shares of the Company (“ADS”) at a price of $13.93 per ADS.
Ambrx Biopharma Inc. announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview at the TD Cowen Oncology Innovation Summit, the Jefferies Healthcare Conference, and the Goldman Sachs 44th Annual Global Healthcare Conference in the coming weeks.
Ambrx Biopharma Inc., or Ambrx, announced that Stephen Glover has joined the Company’s Board of Directors as Chairman.
Ambrx to Present at JMP Securities Life Sciences and RBC Capital Markets Global Healthcare Conferences
Ambrx Biopharma Inc., or Ambrx, announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview at the JMP Securities Life Sciences Conference and RBC Capital Markets Global Healthcare Conference taking place in New York City on May 16th and 17th, respectively.
Ambrx Biopharma Inc., or Ambrx, announced the appointment of Andrew P. Aromando as Chief Operating Officer.
ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results
Ambrx Biopharma Inc announced today that it has been informed by its partner, NovoCodex Biopharmaceuticals, Inc. (NovoCodex), that an interim analysis for ACE-Breast-02, a randomized Phase 3 breast cancer clinical trial investigating Ambrx’s ARX788 has met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a greater progression free survival (PFS) benefit compared to the active control.
ARX517, Ambrx’s Proprietary Anti-PSMA ADC, Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM) today announced encouraging initial data from its ongoing Phase 1 trial (APEX-01 (NCT04662580)) investigating ARX517, Ambrx’s proprietary anti-PSMA ADC, in prostate cancer patients.
Ambrx Biopharma to Host Analyst and Investor Day to Discuss ARX788 in Breast Cancer and ARX517 in Prostate Cancer
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody drug conjugates (ADCs), today announced that it will host a virtual analyst and investor day on February 24 from 12:00pm – 1:00pm ET.
Ambrx Biopharma Strengthens Clinical Leadership with Appointment of Sandra Aung, Ph.D. as Head of Clinical Development
Ambrx Biopharma, Inc. has appointed Sandra Aung, Ph.D., as Executive Vice President, Head of Clinical Development.
Ambrx Biopharma Inc. announced that it received a notice on Nov 23, 2022 from the NYSE that it was not in compliance with the NYSE’s continued listing standards because the average closing price of Ambrx’s American Depositary Shares, each representing seven ordinary shares, had fallen below $1.00 per ADS over a period of 30 consecutive trading days, which is the minimum average closing price per ADS required to maintain continued listing on the NYSE.
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody drug conjugates (ADCs), today announced preliminary safety and efficacy data from its Phase 2 ACE‑Breast-03 study during a Spotlight Poster Presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS).
Interim Data from Ambrx’s Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium
Ambrx Biopharma Inc., or Ambrx announced that interim data from its safety and efficacy study of ARX788 have been selected for a Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium being held December 6th to 10th, 2022, in San Antonio, TX.
An anti-CD70 antibody drug conjugate developed by Ambrx, Inc. has been administered to the first patient in a Phase I study in China. It marks the first ADC in active development that targets CD70.
The executive shuffle continues across the biopharma industry as companies shore up leadership needs with these Movers & Shakers.
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Daniel O’Connor as Chief Executive Officer.
Ambrx Biopharma Inc. announced the company will host a corporate update conference call and live webcast on October 18, 2022 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time, to discuss the company’s strategic review of its development pipeline.